We are a clinical-stage biopha
Pioneering a novel class of therapeutics in Oncology and Immuno-Dysregulated Diseases
ImmixBio Presentation at ThinkEquity Conference October 26, 2022 at 2:00pm ET
We are a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx), which we believe will replace first-line therapies across a multitude of cancer indications.
Enrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher (“PRV”)While their future value is uncertain, PRVs are transferable to other companies and have historically sold for $67 to $350 million according to a January 2020 report […]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe1f9d2e-f230-494b-9bb9-6b910a14f2aa LOS ANGELES, Oct. 25, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that Chief Executive Officer Ilya Rachman, MD, […]
California Soft Tissue Sarcoma Site to lead expanded clinical site consortiumHistorically, high-enrolling lead site has enrolled 2-3 patients per monthClinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess […]